echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The third indication of Cinda PD-1 was approved as the first-line treatment for squamous NSCLC

    The third indication of Cinda PD-1 was approved as the first-line treatment for squamous NSCLC

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On June 3, the official website of the National Medical Products Administration (NMPA) showed that the innovative PD-1 inhibitor Sintilimab injection jointly developed by Innovent and Eli Lilly was used in the first-line squamous non-small cell lung cancer (sqNSCLC) The new indication for treatment (acceptance number: CXSS2000043) was officially approved by NMPA, which is the third indication for the product to be approved
    .

    Sintilimab was developed by Cinda Biologics in the early stage and reached a licensing agreement with Eli Lilly in 2015 to start joint development
    .


    Sintilimab was officially approved in China in December 2018 for the treatment of relapsed/refractory classic Hodgkin’s lymphoma, and was approved in China in February 2021 for combined pemetrexed and platinum For first-line treatment of non-squamous NSCLC


    The approval of this indication is based on a randomized, double-blind, phase III controlled clinical study (ORIENT-12).
    ORIENT-12 is the world's first PD-1 monoclonal antibody combined with gemcitabine and platinum (GP regimen) for advanced sqNSCLC A randomized, double-blind, phase III controlled clinical study of first-line treatment
    .


    A total of 357 subjects were enrolled in the study.


    At the 2020 ESMO conference, Cinda announced the results of the study.
    The mid-term analysis showed that the Sintilimab combination group significantly prolonged the progression-free survival (PFS)
    .


    The latest analysis showed that the median PFS assessed by the Independent Imaging Committee (IRRC) in the Sintilimab combination group and the chemotherapy group were 5.


    In addition to the three approved indications, the listing application of Sintilizumab for the second-line treatment of squamous NSCLC and the first-line treatment of liver cancer in combination with Dayoto (bevacizumab) has also been accepted by the NMPA in January this year
    .

    At present, a total of 8 PD-1/PD-L1 monoclonal antibodies have been approved for marketing in China, including 4 domestically produced first-echelon PD-1 models, from Junshi, Xinda, BeiGene, Hengrui, and these 4 drugs All have been included in the 2020 medical insurance catalogue
    .


    In terms of approved indications, Hengrui PD-1 monoclonal antibody has been approved for 5 indications, and 3 of the other three have been approved


    Domestic PD-1/L1 application and approval status

    From the perspective of sales in 2020, Hengrui Carrelizumab has the highest sales, reaching 4.
    5 billion yuan, followed by Cinda Sindilizumab (2.
    29 billion yuan) and BeiGene Tilelizumab ( 1.
    127 billion yuan), Junshi Teriplimumab (1.
    003 billion yuan)
    .


    In terms of internationalization, with the exception of Hengrui, the other three companies have reached cooperative development agreements with foreign companies.


    Domestic PD-1 sales

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.